The 27th Congress of the European Hematology Association (EHA) 2022, held in Vienna, Austria, and virtually, from 9 - 12 June 2022, saw leading experts from around the world gather to discuss the most exciting updates in the field of hematology. Key updates on CAR-T therapy, transplant research, novel drugs, and more were showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalassemia, and beyond.  
View all videos

EHA 2022

EHA 2022
09–12 June 2022 | Vienna Austria / Online
VJHemOncVJHemOnc@VJHemOnc·
7h

Tracy George (@UUtah) discusses responses to avapritinib in patients with advanced systemic mastocytosis at #EHA2022:

👉http://ow.ly/e4wc50JKBmJ👈

@EHA_Hematology #HemOnc #RareDiseases #MPNsm #Mastocytosis

Reply on Twitter 1543640948202213382Retweet on Twitter 15436409482022133822Like on Twitter 15436409482022133822View Tweet 1543640948202213382
Retweet on TwitterVJHemOnc Retweeted
Mohty_EBMTMohamad Mohty@Mohty_EBMT·
14h

I strongly recommend this beautiful review on mantle cell lymphoma published in the ⁦@NEJM⁩
Amazing advances in this disease over the last 10 years.
⁩ ⁦@TheIACH⁩

Reply on Twitter 1543537157679316994Retweet on Twitter 1543537157679316994102Like on Twitter 1543537157679316994418View Tweet 1543537157679316994
Retweet on TwitterVJHemOnc Retweeted
TheIACHIACH@TheIACH·
18h

Register for the IACH webinar on Managing toxicities in relapsed/refractory multiple myeloma: expert-led case discussions
Thursday July 7, 2022
6:00pm (Paris), 5:00pm (London), 12:00pm (New York), 9:00am (Los Angeles)
FREE Registration: https://us06web.zoom.us/webinar/register/WN_E7T9zIOpTRCqfcihDDCvmg
@Mohty_EBMT

Reply on Twitter 1543481313755365377Retweet on Twitter 15434813137553653773Like on Twitter 15434813137553653779View Tweet 1543481313755365377
VJHemOncVJHemOnc@VJHemOnc·
17h

#iwCART22 | Leading experts John Gribben, Mazyar Shadman, and Saar Gill discuss some of the barriers to CAR-T therapy in CLL & debate the optimal use of CAR-T in CLL:

🎥: http://ow.ly/Mp1V50JA5ko

#CLLsm #LeuSM #ImmunoOnc #HemOnc #CARTcell #tcellrx

Reply on Twitter 1543489852125085696Retweet on Twitter 15434898521250856961Like on Twitter 15434898521250856961View Tweet 1543489852125085696
Load More...

EHA 2022

EHA 2022
09–12 June 2022 | Vienna Austria / Online
The 27th Congress of the European Hematology Association (EHA) 2022, held in Vienna, Austria, and virtually, from 9 - 12 June 2022, saw leading experts from around the world gather to discuss the most exciting updates in the field of hematology. Key updates on CAR-T therapy, transplant research, novel drugs, and more were showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalassemia, and beyond.  
View all videos
VJHemOncVJHemOnc@VJHemOnc·
7h

Tracy George (@UUtah) discusses responses to avapritinib in patients with advanced systemic mastocytosis at #EHA2022:

👉http://ow.ly/e4wc50JKBmJ👈

@EHA_Hematology #HemOnc #RareDiseases #MPNsm #Mastocytosis

Reply on Twitter 1543640948202213382Retweet on Twitter 15436409482022133822Like on Twitter 15436409482022133822View Tweet 1543640948202213382
Retweet on TwitterVJHemOnc Retweeted
Mohty_EBMTMohamad Mohty@Mohty_EBMT·
14h

I strongly recommend this beautiful review on mantle cell lymphoma published in the ⁦@NEJM⁩
Amazing advances in this disease over the last 10 years.
⁩ ⁦@TheIACH⁩

Reply on Twitter 1543537157679316994Retweet on Twitter 1543537157679316994102Like on Twitter 1543537157679316994418View Tweet 1543537157679316994
Retweet on TwitterVJHemOnc Retweeted
TheIACHIACH@TheIACH·
18h

Register for the IACH webinar on Managing toxicities in relapsed/refractory multiple myeloma: expert-led case discussions
Thursday July 7, 2022
6:00pm (Paris), 5:00pm (London), 12:00pm (New York), 9:00am (Los Angeles)
FREE Registration: https://us06web.zoom.us/webinar/register/WN_E7T9zIOpTRCqfcihDDCvmg
@Mohty_EBMT

Reply on Twitter 1543481313755365377Retweet on Twitter 15434813137553653773Like on Twitter 15434813137553653779View Tweet 1543481313755365377
VJHemOncVJHemOnc@VJHemOnc·
17h

#iwCART22 | Leading experts John Gribben, Mazyar Shadman, and Saar Gill discuss some of the barriers to CAR-T therapy in CLL & debate the optimal use of CAR-T in CLL:

🎥: http://ow.ly/Mp1V50JA5ko

#CLLsm #LeuSM #ImmunoOnc #HemOnc #CARTcell #tcellrx

Reply on Twitter 1543489852125085696Retweet on Twitter 15434898521250856961Like on Twitter 15434898521250856961View Tweet 1543489852125085696
Load More...

Latest videos

View all videos
1:55
Updates in immunotherapy for multiple myeloma: BiTEs & novel targets
Adam Sperling • 13 Jun 2022
0:48
Managing patients with T-ALL who relapse or are refractory to first-line treatment
Ajay Vora • 15 Jun 2022
1:37
Case study update: alpelisib for the treatment of PI3K-driven Langerhans cell histiocytosis
Roei Mazor • 10 Jun 2022
3:05
Ruxolitinib, pacritinib, fedratinib or momelotinib for thrombocytopenic patients with myelofibrosis
Claire Harrison • 13 Jun 2022

Press Briefings

View all
3:58
RBP dysregulation and its impact on bone marrow failure and hematopoietic stem cell biology
Pedro Aguilar-Garrido • 11 Jun 2022
7:39
CLIMB THAL-111 and CLIMB SCD-121: exa-cel gene therapy in TDT and SCD
Franco Locatelli • 11 Jun 2022
5:41
Primary results from the Phase III SHINE study: ibrutinib + BR for older patients with MCL
Michael Wang • 11 Jun 2022
5:00
Venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline CLL: updates from GAIA/CLL13
Barbara Eichhorst • 11 Jun 2022

Lymphoma

View all
2:06
Delphinus: daratumumab in R/R T-ALL & T-LBL
Ajay Vora • 15 Jun 2022
2:53
Results from a Phase I study of YTB323, a novel CAR-T therapy in DLBCL
Michael Dickinson • 11 Jun 2022

Multiple Myeloma

View all
1:22
Safety and efficacy of ARI0002h for R/R MM
Carlos Fernandez de Larrea • 10 Jun 2022
1:27
Early results of PHE885, a novel BCMA-directed CAR-T therapy for the treatment of R/R MM
Nikhil Munshi • 9 Jun 2022

Chronic lymphocytic leukemia

View all
1:06
Treatment options for CLL patients with poor prognostic markers
Othman Al-Sawaf • 11 Jun 2022
1:42
Treating CLL after venetoclax or BTK inhibitors
Mazyar Shadman • 10 Jun 2022

Acute lymphoblastic leukemia

View all
0:48
Managing patients with T-ALL who relapse or are refractory to first-line treatment
Ajay Vora • 15 Jun 2022
2:06
Delphinus: daratumumab in R/R T-ALL & T-LBL
Ajay Vora • 15 Jun 2022

Acute myeloid leukemia

View all
1:40
Outcomes & treatment options for patients with AML who relapse after alloHSCT
Eleni Gavriilaki • 11 Jun 2022
1:31
Ongoing trials in AML and HR-MDS: ENHANCE, ENHANCE-2 and ENHANCE-3
Naval Daver • 11 Jun 2022

MPNs

View all
1:51
Responses to avapritinib in patients with advanced systemic mastocytosis
Tracy George • 12 Jun 2022
2:12
Navtemadlin and its role in the treatment of R/R myelofibrosis
Srdan Verstovsek • 22 Jun 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals